GlassScriptPhysician profile
Thomas Vincent Wolff
NPI 1386605996
$8,129.37
in general payments reported to CMS, 2019-2025
31 companies · $1,086 in 2025
The $1,086 reported for 2025 was more than what 95% of Hospitalist providers received nationally (typical 2025 total: $85.87).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,193 · 2020: $584 · 2021: $1,381 · 2022: $1,452 · 2023: $1,108 · 2024: $1,325 · 2025: $1,086.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $3,520.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $3,519.70 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Pfizer INC. | $1,413.41 | 2019-2025 | |
| Abbvie INC. | $1,107.63 | 2021-2025 | Dalvance, Teflaro, Avycaz |
| Novartis Pharmaceuticals Corporation | $890.11 | 2019-2025 | |
| Merck Sharp & Dohme LLC | $716.96 | 2019-2025 | Zerbaxa, Dificid, Recarbrio |
| Janssen Pharmaceuticals, INC | $605.31 | 2019-2024 | Xarelto |
| Boehringer Ingelheim Pharmaceuticals, INC. | $514.45 | 2019-2024 | Jardiance |
| Astrazeneca Pharmaceuticals LP | $458.91 | 2020-2024 | Lokelma, Andexxa, Farxiga |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $415.27 | 2020-2025 | Xifaxan |
| Allergan, INC. | $371.36 | 2019-2020 | |
| Alexion Pharmaceuticals, INC. | $202.69 | 2019-2024 | Ultomiris |
| Melinta Therapeutics, LLC | $194.78 | 2021-2022 | |
| E.R. Squibb & Sons, L.L.C. | $191.20 | 2019-2024 | Eliquis |
| Otsuka America Pharmaceutical, INC. | $178.11 | 2019 | |
| Gilead Sciences, INC. | $154.14 | 2021-2024 | |
| Novo Nordisk INC | $90.30 | 2023-2024 | Rybelsus, Ozempic |
Show all 31 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Boston Scientific Corporation | $83.95 | 2019-2022 | |
| Paratek Pharmaceuticals, INC. | $80.59 | 2022-2023 | Nuzyra |
| Sk Life Science, INC. | $56.34 | 2025 | |
| Amgen INC. | $56.07 | 2019-2024 | Repatha |
| Abbott Laboratories | $48.41 | 2024 | Mitraclip |
| Lundbeck LLC | $47.36 | 2019 | |
| Electromed, INC. | $45.42 | 2023 | Smartvest |
| Philips North America LLC | $43.04 | 2021-2023 | |
| Masimo Corporation | $24.63 | 2025 | |
| Zoll Services LLC (A/K/A Zoll Lifecor Corp) | $24.13 | 2025 | Lifevest |
| Cmp Pharma, INC. | $24.04 | 2021 | |
| Bioxcel Therapeutics, INC. | $23.10 | 2023 | Igalmi |
| Bayer Healthcare Pharmaceuticals INC. | $21.20 | 2024 | |
| Smith+Nephew, INC. | $19.44 | 2025 | Collagenase Santyl |
| Shire North American Group INC | $13.60 | 2019 | |
| Sunovion Pharmaceuticals INC. | $13.42 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Thomas Wolff listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.